Led a $20 million Series D financing in Rivermark Medical, a urology-focused medical device company.
Rivermark Medical develops innovative medical devices, specifically the FloStent, designed to treat Benign Prostatic Hyperplasia (BPH) by restoring urinary flow through outpatient procedures
Rivermark Medical develops innovative medical devices, specifically the FloStent, designed to treat Benign Prostatic Hyperplasia (BPH) by restoring urinary flow through outpatient procedures.